Dr. Evan Graboyes presenting his seminal NDURE randomized trial showing that enhanced patient navigation significantly reduces delays in postoperative radiotherapy and racial disparities. ⁦MUSC Hollings Cancer Center⁩ #HNCS24

Superstar resident Mark Orland, MD presenting our MRD data for high-risk head&neck cancer patients at #HNCS24 Matt Stewart, MD Cleveland Clinic IM

Excited for my first #HNCS24 ! But first, a moment for the beautiful Phoenix weather 🌞

It’s the final day of #HNCS24 !

Looking forward to the talks in supportive care and tx side effects

#HNCS24 : Let’s discuss supportive care in #hncsm tx

Oral mucositis management
🔘Available therapies: Low lvl laser therapy, brushing, flossing, dental care, mucositis mouthwash, ?glutamine
🔘Other agents: avasapasim, doxepin
🔘Future direction: stenting, protons

Final #HNCS24 session: Survivorship after #hncsm tx

🔘Tx can > body image distress (BID)
🔘Managing body image concerns is most commonly omitted in survivorship
🔘BID can be a long term issue
🔘IMAGE-HN can be used to assess BID
🔘CBT is an emerging Tx

As is tradition, the Mayo Clinic Comprehensive Cancer Center Head and Neck Disease Group held its annual retreat right before #HNCS24 . A great time to refine practice recs, develop new research, and start multi-d care initiatives!

#HNCS24 session on viral-driven #hncsm

First up: advances in tx for NPC 👃🏽

🔘Endemic NPC: IO+chemo has benefit in R/M
🔘Non-endemic NPC: use of IO ongoing in R/M
🔘TKI, IO, Chemo combos ongoing in 2L setting

Interesting results from LEAP010 - combo Pembro with Levatinib or Carbozatinib #HNCS24

Evidently increased ORR, possibly PFS but no difference in OS 🤷🏻‍♂️🤔🤔

Loss of OS signal due to effective salvage regimens?

Super proud of my nurse practitioner, Connie Geno, and super star resident, Dan Ebner, who tag teamed for two abstracts at #HNCS24 .

Beautiful morning in Phoenix, Day2 of #HNCS24

cSCC session #HNCS24 moderated by Jessica Geiger and first talk by Shlomo Koyfman from our head&neck group Cleveland Clinic

Great discussion by Melvin LK CHUA at #HNCS24

#HNCS24 : nice figures summarizing current tx options in NPC and future directions

In the future, perhaps we pick tx based on immune response?

#HNCS24 : Biological underpinnings of NPC tx response

🔘EBV > complex genomic changes
🔘SSTR2 potential theranostic target
🔘IO may be useful tx in certain NPC subtypes w ⬆️ immune environment

Wrapping up this session at #HNCS24 : management of dysphagia

🔘IO > late larynx/pharynx edema (worse than chemoRT alone)❗️
🔘Tx: steroids but best management unknown

Big❓: will this late IO dysphagia impact outcomes of HN005 🤔

Congratulations to Eleni Rettig for her informative and intriguing talk on circulating tumor markers at #HNCS24 !

Final talk of #HNCS24 : Financial toxicity in #hncsm tx

🔘Cost of cancer care is 📈
🔘Fin tox = direct cost of tx + indirect costs (travel, etc)
🔘Fin tox > ⬇️ QOL, survival
🔘Fin tox appears ⬆️ in HNC pts
🔘Potential 🛠️: financial navigation

#HNCS24 : Systemic tx in curative NPC
🔘Induction chemo > ⬆️ outcomes but ⬆️ AEs
🔘 Adjuvant chemo > ⬆️ FFS but most trials had no induction; ? OS benefit
🔘Use of IO in induction under investigation

#HNCS24 : Biomarkers for HPV+ OPC

🔘ctDNA appears to ⬆️ w ⬆️ N-stage and certain HPV subtypes (16)
🔘ctDNA has emerging use in surveillance
🔘Remaining ?: use if undetectable at baseline? How to manage false- or imaging- but ctDNA+? RCT needed!
🔘-ctDNA 🙅🏽‍♂️ no dx